Results 21 to 30 of about 205 (161)

Cell-based therapy in prophylaxis and treatment of chronic graft-versus-host disease

Frontiers in Immunology, 2022
Hematopoietic allogeneic stem cell transplantation (allo-SCT) is a curative option for patients with hematological malignancies. However, due to disparities in major and minor histocompatibility antigens between donor and recipient, severe inflammatory ...
Matteo Doglio, Rachel E. Crossland, Ana C. Alho, Ana C. Alho, Olaf Penack, Anne M. Dickinson, Anne M. Dickinson, Georg Stary, Georg Stary, Georg Stary, João F. Lacerda, João F. Lacerda, Günther Eissner, Marit Inngjerdingen   +13 more
doaj   +1 more source

Targeting the Retinoid X Receptor Pathway Prevents and Ameliorates Murine Chronic Graft-Versus-Host Disease

Frontiers in Immunology, 2022
Most allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients receive peripheral blood stem cell grafts resulting in a 30%–70% incidence of chronic graft-versus-host disease (cGVHD), a major cause of mortality and morbidity in long-term ...
Govindarajan Thangavelu, Michael C. Zaiken, Fathima A. Mohamed, Ryan Flynn, Jing Du, Stephanie Y. Rhee, Megan J. Riddle, Ethan G. Aguilar, Angela Panoskaltsis-Mortari, Martin E. Sanders, Bruce R. Blazar   +10 more
doaj   +1 more source

Involvement of Male-Specific Minor Histocompatibility Antigen H-Y in Epidermal Equivalent Allograft Rejection

Cell Transplantation, 1998
This study describes the involvement of male-specific minor histocompatibility antigen H-Y in vitro cultured epidermal equivalent (EE) rejection. Male and female Balb/c or C3H/HeN keratinocytes were isolated and cultured separately.
Marie-Josée Beaulieu, Hui Li, Julie Bergeron, Geneviève Ross, François A. Auger, Mahmoud Rouabhia   +5 more
doaj   +1 more source

Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application

Haematologica, 2008
Background Donor lymphocyte infusion is an effective form of adoptive immunotherapy for hematologic malignancies after allogeneic stem cell transplantation.
Marieke Griffioen, H.M. Esther van Egmond, Helen Barnby-Porritt, Menno A.W.G. van der Hoorn, Renate S. Hagedoorn, Michel G.D. Kester, Nikolai Schwabe, Roel Willemze, J.H. Frederik Falkenburg, Mirjam H.M. Heemskerk   +9 more
doaj   +1 more source

In Silico Analysis of the Minor Histocompatibility Antigen Landscape Based on the 1000 Genomes Project

Frontiers in Immunology, 2018
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is routinely used to treat hematopoietic malignancies. The eradication of residual tumor cells during engraftment is mediated by donor cytotoxic T lymphocytes reactive to alloantigens.
Nadia A. Bykova, Dmitry B. Malko, Grigory A. Efimov   +2 more
doaj   +1 more source

Role of Minor Histocompatibility Antigens in Renal Transplantation [PDF]

American Journal of Transplantation, 2008
In hematopoietic stem cell transplantation (HSCT), disparities between recipients and donors for minor histocompatibility antigens (mHags) have been shown to be related to graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) effects. We investigated the effect of mHag mismatches on kidney allograft survival. Out of 33 785 kidney transplants
A, Heinold, G, Opelz, S, Scherer, A, Ruhenstroth, G, Laux, B, Doehler, T H, Tran   +6 more
openaire   +2 more sources

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

From Adult to Adolescent: Alignment in Clinical Trials and Outcomes in Axial Spondyloarthritis

Arthritis Care &Research, EarlyView.
Spondyloarthritis (SpA) is a group of chronic inflammatory diseases encompassing axial and peripheral forms, with up to 20% of patients developing symptoms before age 16. Despite this substantial pediatric burden, treatment options for juvenile‐onset SpA (JSpA), particularly those with axial disease (axJSpA), remain limited.
Pamela F. Weiss, Judith A. Smith, Robert A. Colbert, Erin Treemarcki, Michael H. Weisman, Walter P. Maksymowych, Hermine I. Brunner, for the Childhood Arthritis and Rheumatology Research Alliance, Spondyloarthritis Research and Treatment Network, and Pediatric Rheumatology Collaborative Study Group Advisory Council   +9 more
wiley   +1 more source

Expanding the immunotherapeutic potential of minor histocompatibility antigens [PDF]

Journal of Clinical Investigation, 2005
Minor histocompatibility antigens (mHAgs) selectively expressed by cells or cell subsets of the hematopoietic system are targets of the T cell-mediated graft-versus-leukemia response that develops following allogeneic hematopoietic stem cell transplantation (HSCT) for the treatment of hematological malignancies.
Eric, Spierings, Els, Goulmy
openaire   +2 more sources

Engineering Immunoregenerative Therapy via an Immunomodulatory Binary Pharmacology Hydrogel Depot for Prolonged Allograft Survival

Advanced Science, EarlyView.
An immunomodulatory hydrogel (iGEL) forms spontaneously upon subcutaneous injection, acting as a tissue‐adhesive depot. It releases anti‐rejection and regenerative agents in response to inflammation, suppressing T‐cell activity, promoting vascular repair, and restoring allograft function without systemic immunosuppression.
Ning Wang, Ruiqi Sun, Yang Fu, Zhonghan Wu, Xinyu Tong, Hong Tang, Wentao Zhao, Zhi Liang, Jintao Zheng, Yanan Guan, Ke Zhou, Penghong Song, Shusen Zheng, Hangxiang Wang, Haiyang Xie   +14 more
wiley   +1 more source